Jacek Kubica

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1557306/publications.pdf

Version: 2024-02-01

242	12,907	94381 37	24961 109
papers	citations	h-index	g-index

280	280	280	12996
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 376, 1713-1722.	13.9	4,179
2	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	13.9	2,211
3	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 807-816.	6.3	934
4	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. Annals of Internal Medicine, 2015, 163, 40-51.	2.0	357
5	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. JAMA - Journal of the American Medical Association, 2018, 319, 1566.	3.8	339
6	Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. American Journal of Cardiology, 2013, 111, 1123-1130.	0.7	239
7	Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. European Heart Journal, 2016, 37, 245-252.	1.0	217
8	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	5.5	207
9	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ, The, 2013, 347, f6530-f6530.	3.0	194
10	Optimal Timing of Coronary Invasive Strategy in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Annals of Internal Medicine, 2013, 158, 261.	2.0	151
11	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. European Heart Journal, 2014, 35, 2295-2302.	1.0	128
12	Cause of Death and Predictors of Allâ€Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association, 2016, 5, e002197.	1.6	127
13	Comparative Efficacy and Safety of Oral P2Y ‹sub›12‹/sub› Inhibitors in Acute Coronary Syndrome. Circulation, 2020, 142, 150-160.	1.6	93
14	First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31â€…379 patients. Open Heart, 2014, 1, e000064.	0.9	88
15	Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention, 2011, 7, 985-994.	1.4	87
16	Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUSâ€PCI study. Journal of Thrombosis and Haemostasis, 2012, 10, 529-542.	1.9	81
17	Meta-Analysis of Time-Related Benefits of Statin Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1753-1764.	0.7	80
18	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. European Heart Journal, 2021, 42, 4638-4651.	1.0	80

#	Article	IF	Citations
19	Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With AcuteÂCoronary Syndrome. JACC: Cardiovascular Interventions, 2015, 8, 201-213.	1.1	69
20	Lowâ€•molecularâ€•weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for STâ€•elevation myocardial infarction: a metaâ€•analysis. Journal of Thrombosis and Haemostasis, 2011, 9, 1902-1915.	1.9	68
21	Critical appraisal of inflammatory markers in cardiovascular risk stratification. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 263-279.	2.7	67
22	Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart, 2011, 97, 98-105.	1.2	64
23	Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. International Journal of Cardiology, 2016, 215, 201-208.	0.8	61
24	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology, 2021, 78, 421-433.	1.2	58
25	Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. European Journal of Clinical Investigation, 2016, 46, 7-14.	1.7	56
26	Diurnal variation in platelet inhibition by clopidogrel. Platelets, 2011, 22, 579-587.	1.1	52
27	High-sensitivity cardiac troponin assays: From improved analytical performance to enhanced risk stratification. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 143-172.	2.7	51
28	Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2018, 53, 495-504.	0.6	50
29	Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death. Circulation, 2011, 124, 2649-2660.	1.6	45
30	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. Annals of Internal Medicine, 2017, 167, 103.	2.0	43
31	Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. Thrombosis Research, 2012, 130, 65-69.	0.8	42
32	Comparison of angiographically guided direct stenting technique with direct stenting and optimal balloon angioplasty guided with intravascular ultrasound. The multicenter, randomized trial results. American Heart Journal, 2007, 154, 669-675.	1.2	41
33	Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thrombosis and Haemostasis, 2014, 112, 224-242.	1.8	41
34	Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. Heart, 2015, 101, 1309-1317.	1.2	40
35	The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction â€“ Baseline Characteristics of the Study Population. Cardiology, 2008, 110, 271-282.	0.6	39
36	Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 193-200.	0.2	39

#	Article	IF	Citations
37	METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorISâ€"The METAMORPHOSIS Trial. Thrombosis and Haemostasis, 2018, 118, 2126-2133.	1.8	39
38	Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention, 2013, 9, 308-315.	1.4	38
39	Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the POLISH STEMI registry. Atherosclerosis, 2010, 210, 516-520.	0.4	37
40	Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: A meta-analysis of randomized trials. Atherosclerosis, 2012, 222, 1-7.	0.4	36
41	Twelve-month results of a Paclitaxel Releasing Balloon in Patients Presenting with In-stent Restenosis First-in-Man (PEPPER) trial. Cardiovascular Revascularization Medicine, 2012, 13, 260-264.	0.3	35
42	Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 561-569.	0.2	34
43	Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. European Journal of Pharmacology, 2014, 742, 47-54.	1.7	30
44	Abciximab as a bridging strategy to overcome morphineâ€"prasugrel interaction in STEMI patients. British Journal of Clinical Pharmacology, 2016, 82, 1343-1350.	1.1	30
45	Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. Thrombosis and Haemostasis, 2017, 117, 718-726.	1.8	30
46	Reliability of heart rate variability measurements in patients with a history of myocardial infarction. Clinical Science, 2010, 118, 195-201.	1.8	29
47	Value of C-Reactive Protein in Predicting Left Ventricular Remodelling in Patients with a First ST-Segment Elevation Myocardial Infarction. Mediators of Inflammation, 2012, 2012, 1-11.	1.4	29
48	Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials. Platelets, 2012, 23, 274-281.	1.1	29
49	Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. Clinical Research in Cardiology, 2013, 102, 279-287.	1.5	29
50	Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?. American Journal of Cardiovascular Drugs, 2014, 14, 79-87.	1.0	29
51	Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis â€" comparison with stable and unstable angina. Inflammation Research, 2005, 54, 187-193.	1.6	28
52	Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Current Medical Research and Opinion, 2014, 30, 813-828.	0.9	28
53	Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. International Journal of Molecular Sciences, 2020, 21, 807.	1.8	28
54	Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. International Journal of Cardiology, 2017, 243, 389-395.	0.8	26

#	Article	IF	Citations
55	Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. Atherosclerosis, 2014, 233, 224-231.	0.4	25
56	Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS ONE, 2017, 12, e0168726.	1.1	25
57	Discrepancies in Assessment of Adherence to Antiplatelet Treatment after Myocardial Infarction. Pharmacology, 2015, 95, 50-58.	0.9	24
58	State of the Art. Cardiology Clinics, 2020, 38, 563-573.	0.9	24
59	Development and Validation of a Practical Model to Identify Patients at Risk of Bleeding After TAVR. JACC: Cardiovascular Interventions, 2021, 14, 1196-1206.	1.1	24
60	Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiology Journal, 2009, 16, 535-44.	0.5	24
61	Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. European Journal of Clinical Investigation, 2011, 41, 667-671.	1.7	23
62	Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention. PLoS ONE, 2014, 9, e102701.	1.1	23
63	Personalized antiplatelet therapy with P2Y 12 receptor inhibitors: benefits and pitfalls. Postepy W Kardiologii Interwencyjnej, 2015, 4, 259-280.	0.1	23
64	Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1161-1168.	1.4	23
65	Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. Biomedicine and Pharmacotherapy, 2021, 143, 112169.	2.5	22
66	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. European Heart Journal, 2021, 42, 2973-2985.	1.0	21
67	Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. International Journal of Molecular Medicine, 2005, 16, 173-80.	1.8	21
68	Correlation between clinical and morphologic findings in unstable angina. American Journal of Cardiology, 1996, 77, 128-132.	0.7	20
69	Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflammation Research, 2012, 61, 725-734.	1.6	20
70	Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary noâ€reflow during primary PCI: The RESTORE observational study. Catheterization and Cardiovascular Interventions, 2021, 97, 602-611.	0.7	20
71	Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiology Journal, 2014, 21, 547-556.	0.5	20
72	Impact of COVIDâ€19 pandemic on acute heart failure admissions and mortality: a multicentre study (COVâ€HFâ€SIRIO 6 study). ESC Heart Failure, 2022, 9, 721-728.	1.4	20

#	Article	IF	Citations
73	No-reflow phenomenon: Achilles' heel of primary coronary angioplasty in acute myocardial infarction. Cardiology Journal, 2008, 15, 1-3.	0.5	20
74	Influence of elastic recoil on restenosis after successful coronary angioplasty in unstable angina pectoris. American Journal of Cardiology, 1993, 71, 659-663.	0.7	19
75	Value of C-Reactive Protein as a Risk Factor for Acute Coronary Syndrome: A Comparison with Apolipoprotein Concentrations and Lipid Profile. Mediators of Inflammation, 2012, 2012, 1-10.	1.4	19
76	Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. Clinical Research in Cardiology, 2014, 103, 855-886.	1.5	19
77	A novel multiplex assay amplifying 13 Y-STRs characterized by rapid and moderate mutation rate. Forensic Science International: Genetics, 2015, 15, 49-55.	1.6	19
78	Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Current Medical Research and Opinion, 2016, 32, 1441-1451.	0.9	19
79	Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry. Mayo Clinic Proceedings, 2019, 94, 1457-1466.	1.4	19
80	Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. PLoS ONE, 2017, 12, e0186013.	1.1	19
81	Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert Review of Cardiovascular Therapy, 2013, 11, 447-462.	0.6	18
82	Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 139-148.	1.4	18
83	Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated expertsâ€™ standpoint. Cardiology Journal, 2018, 25, 291-300.	0.5	18
84	The reliability of noninvasive cardiac output measurement using the inert gas rebreathing method in patients with advanced heart failure. Cardiology Journal, 2008, 15, 63-70.	0.5	18
85	Immunoglobulin E in patients with ischemic heart disease. Cardiology Journal, 2008, 15, 122-8.	0.5	18
86	Stress hyperglycaemia in patients with first myocardial infarction. International Journal of Clinical Practice, 2012, 66, 592-601.	0.8	17
87	ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-of-hospital cardiac arrest survivors improves clinical outcomes: the first European experience. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2013, 21, 22.	1.1	17
88	Metabolism of ticagrelor in patients with acute coronary syndromes. Scientific Reports, 2018, 8, 11746.	1.6	17
89	Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. Frontiers in Cardiovascular Medicine, 2019, 6, 176.	1.1	17
90	C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period. International Journal of Molecular Sciences, 2021, 22, 3169.	1.8	17

#	Article	IF	Citations
91	A critical overview on ticagrelor in acute coronary syndromes. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 105-115.	0.2	16
92	Effect of chokeberry juice consumption on antioxidant capacity, lipids profile and endothelial function in healthy people: a pilot study. Czech Journal of Food Sciences, 2016, 34, 39-46.	0.6	16
93	Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 152-157.	1.4	16
94	Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor. Scientific Reports, 2019, 9, 3924.	1.6	16
95	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 47-54.	1.4	16
96	Left Atrial Size and Wall Motion in Patients with Permanent Ventricular and Atrial Pacing. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 1737-1741.	0.5	15
97	Endothelial function parameters in patients with unstable angina and infection with Helicobacter pylori and Chlamydia pneumoniae. European Journal of Internal Medicine, 2006, 17, 339-342.	1.0	15
98	Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality. European Heart Journal, 2009, 30, 1736-1743.	1.0	15
99	Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials, 2015, 16, 198.	0.7	15
100	New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 2291-2306.	0.9	15
101	High-Dose, but Not Low-Dose, Aspirin Impairs Anticontractile Effect of Ticagrelor following ADP Stimulation in Rat Tail Artery Smooth Muscle Cells. BioMed Research International, 2013, 2013, 1-8.	0.9	14
102	Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. Clinical Biochemistry, 2017, 50, 599-604.	0.8	14
103	Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. International Journal of Cardiology, 2018, 258, 59-67.	0.8	14
104	Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease â€“ A meta-analysis. International Journal of Cardiology, 2018, 269, 292-297.	0.8	14
105	Short-Term Therapies for Treatment of Acute and Advanced Heart Failureâ€”Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. Journal of Clinical Medicine, 2019, 8, 1834.	1.0	14
106	Off-target effects of glycoprotein IIb/IIIa receptor inhibitors. Cardiology Journal, 2014, 21, 458-464.	0.5	14
107	Prediction of high risk of non-adherence to antiplatelet treatment. Kardiologia Polska, 2016, 74, 61-67.	0.3	14
108	How Do Apolipoproteins ApoB and ApoA-I Perform in Patients with Acute Coronary Syndromes. Journal of Medical Biochemistry, 2011, 30, 237-243.	0.7	13

#	Article	IF	Citations
109	Prasugrel in critically ill patients. Thrombosis and Haemostasis, 2017, 117, 1582-1587.	1.8	13
110	A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1035-1043.	1.4	13
111	Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized clinical trials. Cardiology Journal, 2012, 19, 230-242.	0.5	13
112	Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by) Tj ETQq0 0 0 rgBT /Overlock 1 Journal of Cardiology, 2015, 190, 370-375.	0.8	12
113	Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 1659.	1.0	12
114	Ion channel inhibition against COVID-19: A novel target for clinical investigation. Cardiology Journal, 2020, 27, 421-424.	0.5	12
115	Influence of plaque composition on luminal gain after balloon angioplasty, directional atherectomy, and coronary stenting. American Heart Journal, 1995, 130, 971-975.	1.2	11
116	Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions. Current Medical Research and Opinion, 2011, 27, 2133-2144.	0.9	11
117	Value of oral glucose tolerance test in the acute phase of myocardial infarction. Cardiovascular Diabetology, 2011, 10, 21.	2.7	11
118	Impact of Preadmission Morphine on Reinfarction in Patients With STâ€Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Metaâ€Analysis. Clinical Pharmacology and Therapeutics, 2020, 108, 54-62.	2.3	11
119	Myocardial infarction with normal coronary arteriogram: the role of ephedrine-like alkaloids. Medical Science Monitor, 2004, 10, CS15-21.	0.5	11
120	The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease. Cardiology Journal, 2008, 15, 344-50.	0.5	11
121	Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent. Journal of Experimental Pharmacology, 2021, Volume 13, 957-970.	1.5	11
122	Atrioventricular Conduction Disturbances in Patients with Sinoatrial Node Disease and Atrial Pacing. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 2074-2076.	0.5	10
123	Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite?. Thrombosis and Haemostasis, 2016, 116, 1140-1149.	1.8	10
124	The Use of Biochip Cardiac Array Technology for Early Diagnosis of Acute Coronary Syndromes. Journal of Medical Biochemistry, 2009, 28, 293-299.	0.7	9
125	Acetylsalicylic acid resistance risk factors in patients with myocardial infarction. Pharmacological Reports, 2015, 67, 952-958.	1.5	9
126	The number of circulating endothelial progenitor cells in healthy individuals â€“ Effect of some anthropometric and environmental factors (a pilot study). Advances in Medical Sciences, 2015, 60, 58-63.	0.9	9

#	Article	IF	Citations
127	Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opinion on Pharmacotherapy, 2018, 19, 1415-1425.	0.9	9
128	Transcathether aortic valve implantation with the new repositionable self-expandable Medtronic Evolut R vs. CoreValve system. Journal of Cardiovascular Medicine, 2019, 20, 226-236.	0.6	9
129	von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo. Thrombosis and Haemostasis, 2020, 120, 1282-1290.	1.8	9
130	Long-Term Outcomes Following Drug-Eluting Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis (DEB-Dragon-Registry). Circulation: Cardiovascular Interventions, 2021, 14, e010868.	1.4	9
131	Manual vs mechanical thrombectomy during PCI for STEMI: a comprehensive direct and adjusted indirect meta-analysis of randomized trials. American Journal of Cardiovascular Disease, 2013, 3, 146-57.	0.5	9
132	IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study. Cardiology Journal, 2022, 29, 140-147.	0.5	9
133	Threshold parameters of left main coronary artery stem stenosis based on intracoronary ultrasound examination. Kardiologia Polska, 2005, 63, 223-31; discussion 232-3.	0.3	9
134	Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study. BMJ Open, 2017, 7, e013218.	0.8	8
135	Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy Volunteers. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 430-436.	1.3	8
136	Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. Cardiology Journal, 2020, 27, 780-788.	0.5	8
137	Management and predictors of clinical events inÂ75Â686Âpatients with acute myocardial infarction. Kardiologia Polska, 2022, 80, 468-475.	0.3	8
138	Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: A systematic review and meta-analysis of randomized trials. Atherosclerosis, 2013, 229, 482-488.	0.4	7
139	Impact of lipid markers and high-sensitivity C-reactive protein on the value of the 99th percentile upper reference limit for high-sensitivity cardiac troponin I. Clinica Chimica Acta, 2016, 462, 193-200.	0.5	7
140	Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2018, 16, 419-429.	0.6	7
141	Transcatheter aortic valve replacement with Lotus and Sapien 3 prosthetic valves: a systematic review and meta-analysis. Journal of Thoracic Disease, 2020, 12, 893-906.	0.6	7
142	Endogenous fibrinolysisâ€"Relevance to clinical thrombosis risk assessment. European Journal of Clinical Investigation, 2021, 51, e13471.	1.7	7
143	Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society. Kardiologia Polska, 2020, 78, 825-834.	0.3	7
144	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiology Journal, 2020, 27, 661-676.	0.5	7

#	Article	IF	Citations
145	Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. Advances in Medical Sciences, 2022, 67, 18-22.	0.9	7
146	One-year outcomes of left main coronary artery stenting in patients with cardiogenic shock. Cardiology Journal, 2007, 14, 67-75.	0.5	7
147	Smokers versus non-smokers undergoing percutaneous transluminal coronary angioplasty: The impact of clinical and procedural characteristics on in-hospital mortality. Cardiology Journal, 2007, 14, 482-92.	0.5	7
148	Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report. Cardiology Journal, 2008, 15, 530-6.	0.5	7
149	Circulatory support with Impella CP device during high-risk percutaneous coronary interventions: initial experience in Poland. Postepy W Kardiologii Interwencyjnej, 2016, 3, 254-257.	0.1	6
150	State of the art: Oral antiplatelet therapy. JRSM Cardiovascular Disease, 2016, 5, 204800401665251.	0.4	6
151	Transcatheter Aortic Valve Replacement with Self-Expandable ACURATE neo as Compared to Balloon-Expandable SAPIEN 3 in Patients with Severe Aortic Stenosis: Meta-Analysis of Randomized and Propensity-Matched Studies. Journal of Clinical Medicine, 2020, 9, 397.	1.0	6
152	Characteristics of patients from the Polish Registry of Acute Coronary Syndromes during the COVID-19 pandemic: the first report. Kardiologia Polska, 2021, 79, 192-195.	0.3	6
153	Glasgow Coma Scale score of more than four on admission predicts in-hospital survival in patients after out-of-hospital cardiac arrest. American Journal of Emergency Medicine, 2021, 42, 90-94.	0.7	6
154	Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?. Cardiology Journal, 2021, , .	0.5	6
155	Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor â€" NARCOTIC trial. Cardiology Journal, 2022, 29, 432-440.	0.5	6
156	Comparison of temperature measurements in esophagus and urinary bladder in comatose patients after cardiac arrest undergoing mild therapeutic hypothermia. Cardiology Journal, 2020, 27, 735-741.	0.5	6
157	Assessment of Selected Baseline and Post-PCI Electrocardiographic Parameters as Predictors of Left Ventricular Systolic Dysfunction after a First ST-Segment Elevation Myocardial Infarction. Journal of Clinical Medicine, 2021, 10, 5445.	1.0	6
158	Gender differences and in-hospital mortality in patients undergoing percutaneous coronary interventions. Kardiologia Polska, 2008, 66, 632-9; discussion 640-1.	0.3	6
159	Occurrence and predictors of left ventricular systolic dysfunction at hospital discharge and in long-term follow-up after acute myocardial infarction treated with primary percutaneous coronary intervention. Kardiologia Polska, 2012, 70, 329-40.	0.3	6
160	Use of time-resolved fluorescence spectroscopy to evaluate diagnostic value of collagen degradation products. Journal of Biomedical Optics, 2015, 20, 051039.	1.4	5
161	Admission glucose and left ventricular systolic function in non-diabetic patients with acute myocardial infarction. Heart and Vessels, 2016, 31, 298-307.	0.5	5
162	Impact of levosimendan on platelet function. Thrombosis Research, 2017, 159, 76-81.	0.8	5

#	Article	IF	Citations
163	Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opinion on Pharmacotherapy, 2018, 19, 1389-1398.	0.9	5
164	Risk of Statin-Induced Hypertransaminasemia. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 131-140.	1.2	5
165	Mild therapeutic hypothermia after out-of-hospital cardiac arrest: What does really matter?. Cardiology Journal, 2021, 28, 293-301.	0.5	5
166	Pharmacokinetic Modeling of Morphineâ€™s Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers. Frontiers in Physiology, 2021, 12, 663170.	1.3	5
167	Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society. Cardiology Journal, 2019, 26, 1-7.	0.5	5
168	Anti-aggregation therapy in patients with acute coronary syndrome â€" recommendations for medical emergency teams. Expertsâ€™ standpoint. Kardiologia Polska, 2017, 75, 399-408.	0.3	5
169	ISAR-REACT 5 â€" What have we learned?. Cardiology Journal, 2019, 26, 427-428.	0.5	5
170	Immunoglobulin E as a marker of the atherothrombotic process in patients with acute myocardial infarction. Cardiology Journal, 2007, 14, 266-73.	0.5	5
171	Effects of coronary angioplasty on left ventricular function. American Journal of Cardiology, 1993, 72, G119-G123.	0.7	4
172	The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials, 2017, 18, 316.	0.7	4
173	ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial. BMJ Open, 2021, 11, e043330.	0.8	4
174	Safety and Efficacy of Different Antithrombotic Strategies after Transcatheter Aortic Valve Implantation: A Network Meta-Analysis. Thrombosis and Haemostasis, 2022, 122, 216-225.	1.8	4
175	Diagnostic Performance of Selected Baseline Electrocardiographic Parameters for Prediction of Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction. Journal of Clinical Medicine, 2021, 10, 2405.	1.0	4
176	Influence of cardiac resynchronization therapy on oxidative stress markers in patients with chronic heart failure. Cardiology Journal, 2014, 21, 576-582.	0.5	4
177	Does mobilisation of CD34+ stem cells along with VEGF, angiogenin, IL-6, IL-8, and hsCRP levels allow predicting the direction of left ventricular ejection fraction and wall motion score index changes in patients with myocardial infarction?. Kardiologia Polska, 2013, 71, 464-471.	0.3	4
178	Predicted and observed in-hospital mortality after left main coronary artery stenting in 204 patients. Cardiology Journal, 2008, 15, 268-76.	0.5	4
179	Transesophageal Programmed Atrial Pacing as a Method of Selecting Patients with Sick Sinus Syndrome for Permanent Atrial Pacing. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 1655-1661.	0.5	3
180	Transesophageal Atrial Pacing Complications in Patients Suspected of Tachy-Brady Syndrome. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 2048-2053.	0.5	3

#	Article	IF	Citations
181	Neither Cyclosporine nor Tacrolimus Deteriorate Endothelial Function in Renal Transplant Recipients Assessed With Reactive Hyperernia Index. Transplantation Proceedings, 2013, 45, 1567-1570.	0.3	3
182	Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. Expert Review of Cardiovascular Therapy, 2016, 14, 1361-1370.	0.6	3
183	Safety and efficacy of selfâ€apposing Stentys drugâ€eluting stent in left main coronary artery PCI: Multicentre LMâ€STENTYS registry. Catheterization and Cardiovascular Interventions, 2019, 93, 574-582.	0.7	3
184	Diurnal variations in tissue factor and tissue factor pathway inhibitor concentrations in relation to on-treatment platelet reactivity: an analysis of patients with acute myocardial infarction. Platelets, 2020, 31, 877-883.	1.1	3
185	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiology Journal, 2021, 28, 607-614.	0.5	3
186	Long-term outcome of rotational atherectomy according to burr-to-artery ratio and changes in coronary artery blood flow: Observational analysis. Cardiology Journal, 2021, , .	0.5	3
187	Influence of QRS duration and axis on response to cardiac resynchronization therapy in chronic heart failure with reduced left ventricular ejection fraction: A single center study including patients with left bundle branch block. Cardiology Journal, 2020, 27, 575-582.	0.5	3
188	Impact of ticagrelor administration strategy on its pharmacokinetics and pharmacodynamics in patients with unstable angina pectoris: a protocol of a randomized study. Medical Research Journal, 2016, 1, 10-14.	0.1	3
189	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiology Journal, 2021, , .	0.5	3
190	Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study. Cardiology Journal, 2021, , .	0.5	3
191	Associations between selected angiographic parameters and the number of CD34+ cells and plasma levels of vascular endothelial growth factor and angiogenin in patients with ST-segment elevation myocardial infarction. Polish Archives of Internal Medicine, 2015, 125, 132-140.	0.3	3
192	Diabetogenic effect of statins: a comprehensive review on the clinical relevance, underlying pathomechanisms and rationale for tailored statin therapy. Medical Research Journal, 2016, 3, 145-153.	0.1	3
193	Medical emergency team interventions in patients with ST-segment elevation myocardial infarction in Poland in 2018. Kardiologia Polska, 2020, 78, 292-299.	0.3	3
194	Left ventricle systolic volume in vasovagal syncope patients. Folia Morphologica, 2003, 62, 175-8.	0.4	3
195	Percutaneous coronary angioplasty in elderly patients: Assessment of in-hospital outcomes. Cardiology Journal, 2007, 14, 143-54.	0.5	3
196	Usefulness of optical coherence tomography in the assessment of atherosclerotic culprit lesions in acute coronary syndromes. Comparison with intravascular ultrasound and virtual histology. Cardiology Journal, 2008, 15, 561-3.	0.5	3
197	Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor. Journal of Clinical Medicine, 2022, 11, 1124.	1.0	3
198	The impact of mild therapeutic hypothermia on platelet reactivity in comatose survivors of cardiac arrest with acute myocardial infarction treated with ticagrelor. Cardiology Journal, 2022, , .	0.5	3

#	Article	IF	Citations
199	"Sirolimus or paclitaxel drug eluting stent in left main disease: The winner isâ€¦ ". International Journal of Cardiology, 2011, 152, 387.	0.8	2
200	Long-Term Outcomes Following Coronary Revascularizations in DiabetesÂMellitus. Journal of the American College of Cardiology, 2020, 76, 2208-2211.	1.2	2
201	â€œProtocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarctionâ€: study protocol for a randomized controlled trial. Trials, 2020, 21, 744.	0.7	2
202	Pharmacodynamic and clinical efficacy of reduced ticagrelor maintenance doses in patients with coronary artery disease. Current Medical Research and Opinion, 2021, 37, 195-206.	0.9	2
203	Antiplatelets in acute coronary syndrome in Poland â€“ from guidelines to clinical practice. Postepy W Kardiologii Interwencyjnej, 2021, 17, 141-154.	0.1	2
204	Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study â€” preliminary results. Cardiology Journal, 2021, 28, 58-66.	0.5	2
205	Endothelial dysfunction in acute coronary syndrome without ST segment elevation in the presence of Helicobacter pylori infection. Kardiologia Polska, 2002, 57, 533-4; discussion 541.	0.3	2
206	Periprocedural soluble P- and E-selectin levels fail as predictors of clinical restenosis in patients treated with elective coronary stenting. International Journal of Molecular Medicine, 2007, 19, 187.	1.8	1
207	High-risk percutaneous coronary intervention with Impella CP hemodynamic support. A case series and method presentation. Postepy W Kardiologii Interwencyjnej, 2017, 1, 67-71.	0.1	1
208	COVID-19 pandemic year in the cardiology department. Medical Research Journal, 2021, 6, 40-46.	0.1	1
209	Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2021, 10, 1278.	1.0	1
210	Percutaneous left atrial appendage closure for thromboembolic prophylaxis in patients with atrial fibrillation. The impact of operatorâ€™s experience on the procedure course. Medical Research Journal, 2016, 3, 160-164.	0.1	1
211	Device-associated thrombus after percutaneous left atrial appendage closure: a case report and literature review. Medical Research Journal, 2016, 1, 48-52.	0.1	1
212	The influence of metoclopramide on pharmacokinetics and pharmacodynamics of ticagrelor in patients with unstable angina pectoris receiving concomitant treatment with morphine â€” a protocol of a randomized trial. Medical Research Journal, 2016, 1, 68-71.	0.1	1
213	The rationale for Multilevel Educational and Motivational Intervention in Patients after Myocardial Infarction (MEDMOTION) project is to support multicentre randomized clinical trial Evaluating Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome (ELECTRA â€“ SIRIO 2). Medical Research Journal, 2020, 5, 244-249.	0.1	1
214	Antibodies to Chlamydia pneumoniae and haemostatic factors in acute coronary syndrome without ST segment elevation. Kardiologia Polska, 2002, 57, 297-305.	0.3	1
215	Assessment of left ventricular function by isometric handgrip exercise after thrombolysis in patients with refractory unstable angina. American Journal of Cardiology, 1993, 72, G140-G144.	0.7	0
216	Detection of Cardiac-Related Diseases Using Nonlinear Analysis of Short-Term ECG Signal with Aural Stimuli. , 2008, , .		0

#	Article	IF	Citations
217	Ticagrelor in the treatment of coronary artery disease patients. Clinical Practice (London, England), 2012, 9, 373-390.	0.1	0
218	Caution in interpreting the findings from small observational studies. International Journal of Cardiology, 2012, 160, 71.	0.8	0
219	Endothelial cell markers in coronary artery disease. Postepy W Kardiologii Interwencyjnej, 2012, 4, 275-279.	0.1	0
220	Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention. JAMA - Journal of the American Medical Association, 2021, 325, 890.	3.8	0
221	Cost-effectiveness of levosimendan in patients with exacerbation of chronic heart failure â€" a single-center perspective. Medical Research Journal, 2021, 6, 114-118.	0.1	0
222	Out-of-hospital cardiac arrest and COVID-19 pandemic. Medical Research Journal, 2021, 6, 83-85.	0.1	0
223	Genetyczne aspekty farmakokinetyki i farmakodynamiki klopidogrelu. Folia Cardiologica, 2015, 10, 275-282.	0.1	0
224	Does morphine administration affect ticagrelor conversion to its active metabolite in patients with acute myocardial infarction? A sub-analysis of the randomized, double-blind, placebo- -controlled IMPRESSION trial. Medical Research Journal, 2015, 3, 100-106.	0.1	0
225	A systematic review on the role of bivalirudin in patients undergoing percutaneous coronary interventions: primus inter pares or a falling star?. Medical Research Journal, 2015, 3, 79-88.	0.1	0
226	Variability of prasugrel antiplatelet effect in patients with acute coronary syndrome. Medical Research Journal, 2015, 3, 117-124.	0.1	0
227	ARCHITECT STAT High Sensitive Troponin I Familiarization Study (FAM) in the Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University in Bydgoszcz, Poland. Medical Research Journal, 2015, 3, 107-112.	0.1	0
228	Successful reduction of severe mitral regurgitation after implantation of four MitraClip devices. Medical Research Journal, 2016, 3, 176-179.	0.1	0
229	Impact of prior statin therapy on evaluation of the inflammatory process and cortisol concentration in patients with the first ST-segment elevation myocardial infarction undergoing coronary angioplasty with bare metal stent implantation. Medical Research Journal, 2016, 1, 28-36.	0.1	0
230	Mild therapeutic hypothermia for patients with acute coronary syndrome and cardiac arrest treated with percutaneous coronary intervention (UNICORN). The design and rationale for the prospective, observational, multicenter study. Medical Research Journal, 2016, 1, 23-27.	0.1	0
231	Platelet reactivity during mild therapeutic hypothermia in patients with acute myocardial infarction treated with ticagrelor: study protocol of a single-centre study. Medical Research Journal, 2017, 1, 115-119.	0.1	0
232	Anti-aggregation therapy in patients with acute coronary syndrome â€" recommendations for medical emergency teams. Expertsâ€™ standpoint. Kardiologia Polska, 2017, 75, 47-56.	0.3	0
233	Znaczenie kliniczne interakcji morfinaâ€“doustni antagoniÅ›ci pÅ‚ytkowego receptora P2Y12 u chorych z ostrym zespoÅ‚em wieÅ„cowym â€" komentarz do artykuÅ‚u. Kardiologia Polska, 2017, 75, 58-59.	0.3	0
234	The influence of naloxone on pharmacokinetics and pharmacodynamics of ticagrelor in patients with unstable angina pectoris receiving concomitant treatment with morphine â€" a protocol of a randomized trial. Medical Research Journal, 0, , .	0.1	0

#	Article	IF	Citations
235	Rationale and design of PREvalence of DyspneA in patients treated with TicagrelOR (PREDATOR) program. Medical Research Journal, 0, , .	0.1	0
236	Carvedilol â€“ is it still the primus inter pares among b-blockers?. Medical Research Journal, 2018, 3, 165-174.	0.1	0
237	75-year-old man with lung cancer obscured by an implantable cardioverter-defibrillator â€” case report. Medical Research Journal, 2019, 4, 63-66.	0.1	0
238	Creative scientific dispute â€” different points of view on the protocol and execution of the ISAR-REACT 5 trial. Medical Research Journal, 2020, 5, 41-45.	0.1	0
239	Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients. Cardiology Journal, 2021, , .	0.5	0
240	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Medical Research Journal, 2020, 5, 177-190.	0.1	0
241	Analysis of the relationship between the inner structure and the magnitude of atherosclerotic plaques. Folia Morphologica, 2003, 62, 369-75.	0.4	0
242	Thrombolysis in cardiac arrest: Initial enthusiasm tempered. Cardiology Journal, 2007, 14, 422-3.	0.5	0